Yes, I’m Angry. Here’s Why Our Industry Needs to Remember Its Purpose.

Antique balance scale with a glowing heart on one side and coins on the other.

If you’ve read my blog for a while, you may have noticed a recurring theme—and you might assume I’m an angry blogger. You would be correct. I’m angry because I care deeply about this industry. My entire career has been spent in pharma commercialization. Over the years, I have witnessed amazing scientists, tireless clinicians, and brilliant commercial teams bring life-saving medicines to the patients who need them most. When healthcare companies get this right, there are few industries on Earth that build more human value. But somewhere along the way, too many organizations shifted their focus.

The primary question changed:

Old Focus: “How do we better serve patients?”

New Focus: “How do we please Wall Street this quarter?”

Those are two fundamentally different mindsets.

When Patients Turn into Spreadsheets

Look, I understand reality. Publicly traded companies have responsibilities to shareholders. Profit fuels research, manufacturing, and innovation—without healthy, sustainable businesses, life-saving medicines simply won’t reach the people who need them.

But when the quarterly earnings report becomes the primary goal, humanity gets lost.

  • Patients turn into numbers on a spreadsheet.
  • Promising drug programs are shelved because they don’t hit short-term profit thresholds.
  • Commercial teams are reorganized (yet again) just to trim operational costs.
  • Remaining employees are expected to do the work of three people so a layoff looks good on the next earnings call.

It makes my blood boil. Companies built on the promise of saving lives are making critical decisions based on financial pundits instead of patient outcomes.

The Silent Cost: Discarding Experience

Here’s what angers me even more: what is happening to our workforce.

Every single week, I hear from smart, talented professionals with 20+ or 30+ years of industry experience who suddenly find themselves laid off. “Made redundant”—as one company politely phrased it to a colleague recently.

These are seasoned experts. They know drug launches inside and out. They live and breathe market access, have mastered payer strategy, and know how to navigate brutal regulatory environments.

Yet overnight, they are labeled:

  • Too expensive.
  • Too old.
  • Overqualified.

Let’s be honest about what’s happening here: it’s ageism.

We mask it behind comfortable corporate jargon like “organizational redesign” or “workforce optimization.” But call it what you want—smart people see right through it. The underlying message to experienced workers is clear: You’re too expensive, and we don’t need you.

Unbelievable.

Why Senior Leadership Matters Now More Than Ever

Throwing away institutional knowledge makes zero sense—especially today, when healthcare has never been more complex:

  • Market access is a constant battleground.
  • Pricing pressure isn’t going away.
  • Regulators are demanding deeper, more complex data.
  • Patients expect personalized, modern engagement.
  • Product launches require seamless coordination across dozens of specialized teams.

In an environment this challenging, senior leaders aren’t a luxury—they’re critical.

Experienced leaders have navigated product failures, triumphant launches, reimbursement struggles, aggressive new competitors, and wild market surprises. They have already paid the price of costly mistakes, which means they know how to avoid them.

Replacing veteran leaders with entry-level talent might make this quarter’s balance sheet look tidy. But someone eventually pays the price. More often than not, it’s the patients, the customers, and the remaining employees who are left scrambling to solve problems that experienced team members already knew how to fix.

Innovation Doesn’t Eliminate the Need for Expertise

I’m not arguing against evolution. Healthcare, like any industry, must adapt. Technology is transforming how we operate, and AI is going to revolutionize pharma commercialization in ways we can barely imagine yet.

But technology does not render experience obsolete.

Smart organizations don’t trade experience for innovation; they bring them together. They recognize that fresh ideas and deep-rooted expertise are complementary forces.

Remembering Our Purpose

That’s why I’m angry. I’m not mad at progress or change. I’m angry at choices made as if they don’t impact the core reason many of us entered healthcare in the first place.

  • Patients shouldn’t be collateral damage in strategies designed to pump short-term earnings.
  • Employees shouldn’t be treated as line-item expenses on a financial statement.
  • This industry—which has achieved some of the most remarkable scientific feats in human history—deserves leaders who balance business sustainability with our true purpose.

Does that sound naive?

Maybe. Or maybe we just forgot why we started.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply